15 December 2023
IXICO plc
("IXICO" or "Group" or "Company")
Change of Auditor
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that the Board has approved the appointment of Moore Kingston Smith LLP ("MKS") as the Company's new provider of external audit related services and that Grant Thornton UK LLP ("Grant Thornton") has resigned as the Company's auditor with immediate effect.
As detailed further in the Annual Report and Accounts 2023, this appointment follows a competitive tender process, running from May 2023 and concluding in October 2023, for the Group's FY24 audit services. A resolution to appoint MKS as auditors of the Company will be put forward at the 2024 Annual General Meeting, which will take place at 10:30am on 25 January 2024.
Grant Thornton has been involved in auditing the Group since 2013 and we thank them for their services over this time. Grant Thornton has confirmed to the Company that there are no matters connected with their ceasing to hold office that need to be brought to the attention of the members or creditors of the Company for the purposes of section 519 of the Companies Act 2006.
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 | ||
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| ||
| |
| ||
| Cavendish Securities PLC (Nominated adviser and sole broker) | +44 (0) 20 7397 8900 | ||
| Giles Balleny (Corporate Finance) Charlie Combe (ECM) | |
| |
| Michael F Johnson / Tamar Cranford Smith (Sales) | |
| |
|
|
|
| |
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.